Retatrutide cuts sleep apnoea severity in two phase 3 trials published in NEJM
_Image credit: Healio_
In the TRIUMPH-OSA trials, weekly retatrutide cut breathing interruptions during sleep far more than placebo over 80 weeks in adults with moderate-to-severe sleep apnoea and obesity, with or without type 2 diabetes. Weight loss reached up to 22.2% without diabetes. Retatrutide is still investigational and is not licensed in the UK.
Source: Healio (11 Nov 2026). Image: Healio.